Introduction
============

Patients with chronic pain often suffer with depressive symptoms. Previous clinical studies have demonstrated that the incidence of comorbid chronic pain and depression is approximately 30 to 50% ([@B4]; [@B13]; [@B22]). Thus, comorbid pain and depression are a serious clinical, social, and economic issue that needs to be resolved. However, the underlying mechanisms and therapeutic strategies for managing this comorbidity remain undetermined.

Non-steroidal anti-inflammatory drugs (NSAIDs) and opioid drugs are widely used for pain relief. However, several studies have shown that NSAIDs are not effective in approximately half of patients with chronic pain ([@B35]; [@B32]; [@B26]). Furthermore, although opioids have powerful analgesic effects, their considerable side effects limit their widespread use when administered in larger doses ([@B25]). Opioid crisis and drug overdose-related deaths are a serious problem in the United States ([@B33]). New treatment options for opioid-use disorders are sorely needed. Although analgesics and antidepressant agents are currently prescribed for depression in patients with somatic symptoms or chronic pain, drugs without significant side effects are needed for treating the comorbidity of pain and depression.

Nuclear factor (erythroid-derived 2)-like 2 (Nrf2) is a transcription factor that plays a central role in cellular defense against oxidative and electrophilic insults ([@B15]; [@B16]; [@B30]; [@B31]; [@B6]; [@B37]). Under normal conditions, Nrf2 is repressed by Kelch-like erythroid cell-derived protein with CNC homology (ECH)-associated protein 1 (Keap1), which is an adaptor protein for Nrf2 degradation ([@B30]; [@B31]; [@B37]). During oxidative stress, including inflammation, Nrf2 is derepressed, which activates the transcription of cytoprotective genes. In addition, the Keap1-Nrf2 system is also involved in attenuating inflammation-associated pathogenesis ([@B15]; [@B30]; [@B21]; [@B31]; [@B37]). In the learned helplessness (LH) paradigm, Keap1 and Nrf2 protein levels in the prefrontal cortex and dentate gyrus of the hippocampus in LH (susceptible) rats were lower than those in control and non-LH (resilient) rats ([@B40]). Furthermore, the expression of Keap1 and Nrf2 proteins in the parietal cortex of depressed patients was lower than that in controls, suggesting that Keap1-Nrf2 signaling contributes to stress resilience, which plays a key role in the pathophysiology of depression ([@B40]).

Nrf2 signaling pathway has been commonly reported to be activated by food supplements and natural compounds ([@B5]; [@B18], [@B19]; [@B8]). Sulforaphane (SFN), a natural potent anti-inflammatory compound, is an organosulfur compound derived from glucoraphanin (a glucosinolate precursor of SFN) which is fully enriched in cruciferous vegetables ([@B42]; [@B10]; [@B7]; [@B9]). SFN is reported to have potent anti-inflammatory effects through the activation of Nrf2. Previously, we reported that pretreatment with SFN has prophylactic effects on depression-like phenotype and dendritic spine changes in an inflammation-induced model of depression ([@B41]), and that novel Nrf2 activators (TBE-31 and MCE-1) demonstrate antidepressant effects in an inflammation model of depression ([@B39]). Furthermore, dietary intake of glucoraphanin during juvenile and adolescent stages confers resilience to chronic social defeat stress in adulthood ([@B39]). Previous reports have shown that intrathecal administration of SFN attenuated mechanical allodynia and thermal hyperalgesia in spinal nerve transfection-injured mice ([@B14]), and that SFN inhibited complete Freund's adjuvant-induced allodynia and hyperalgesia ([@B23]). Taken together, it is likely that SFN is a potential natural compound for treating comorbid pain and depression.

The purpose of the present study was to examine the role of the Keap1-Nrf2 signaling system in selected tissues following surgery for spared nerve injury (SNI). Furthermore, we investigated whether abnormalities in behaviors and Keap1-Nrf2 levels in selected tissues following SNI are attenuated with subsequent administration of SFN. Finally, we examined whether pretreatment with SFN could prevent pain and anhedonia-like symptoms and alter Keap1-Nrf2 protein expression in selected tissues following SNI.

Materials and Methods {#s1}
=====================

Animals
-------

Male Sprague Dawley (SD) rats (weighing 180--230 g) were purchased from the Laboratory Animal Centre of Tongji Medical College, Huazhong University of Science and Technology (Wuhan, China). A total of 98 rats were enrolled and were divided into groups in accordance with the random number table. The animals were housed under 12 h light/dark cycle with free access to food and water. Procedures of this animal experiment were in accordance with the National Institute of Health Guide for the Care and Use of Laboratory Animals. The experimental protocols were approved by the Experimental Animal Committee of Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology (No. 34724466).

Experimental Design
-------------------

As shown in **Figure [1A](#F1){ref-type="fig"}**, rats were acclimated to environment for 6 days. Then the mechanical withdrawal threshold (MWT) was performed 1 day before the SNI surgery for baseline measurement. MWT and sucrose preference test (SPT) were implemented from day 2 to 5, 9 to 12, and 16 to 19 after surgery, respectively. Twenty-three days after SNI surgery, medial prefrontal cortex (mPFC), hippocampus, and nucleus accumbens (NAc) of brain, L2-5 spinal cord, skeletal muscle, and liver were collected. Tissue samples were stored at -80°C before Western blot analysis. A single dose of SFN (30 mg/kg, Absin Bioscience Inc., Shanghai, China) was intraperitoneally injected before or after SNI surgery to investigate its effects on pain and anhedonia symptoms (**Figures [3A](#F3){ref-type="fig"}, [5A](#F5){ref-type="fig"}**). The dose (30 mg/kg) of SFN was used as previously reported ([@B28], [@B29]; [@B41]).

![The results of MWT and SPT in sham, anhedonia-susceptible, and anhedonia-resilient rats. **(A)** The schedule of the experiment. SNI surgery was performed on day 0 after acclimation. MWT was measured on day 7, 14, and 21 after SNI, respectively. SPT was performed on day 5, 12, and 19 after SNI, respectively. **(B)** Dendrogram of hierarchical clustering analysis. A total of 25 SNI rats were divided into anhedonia-susceptible and anhedonia-resilient groups by SPT results. **(C)** MWT \[Time: *F*~(3,21)~ = 38.352~,~ *P* \< 0.001; Group: *F*~(2,14)~ = 66.232~,~ *P* \< 0.001; Interaction: *F*~(6,42)~ = 9.711~,~ *P* \< 0.001\] was measured on day 7, 14, and 21 in the sham, anhedonia-resilient, and anhedonia-susceptible groups after SNI, respectively. Data are shown as mean ± SEM (*n* = 8). ^∗∗∗^*P* \< 0.001, susceptible group vs. sham group; ^\#\#\#^*P* \< 0.001, resilient group vs. sham group. **(D)** SPT \[Time: *F*~(2,14)~ = 2.523~,~ *P* = 0.13; Group: *F*~(2,14)~ = 30.388~,~ *P* \< 0.001; Interaction: *F*~(4,28)~ = 0.687~,~ *P* = 0.609\] was measured in the sham, anhedonia-resilient, and anhedonia-susceptible groups on day 5, 12, and 19 after SNI, respectively. Data are shown as mean ± SEM (*n* = 8). ^∗^*P* \< 0.05, ^∗∗^*P* \< 0.01, or ^∗∗∗^*P* \< 0.001. MWT, mechanical withdrawal test; N.S., not significant; SNI, spared nerve injury; SPT, sucrose preference test.](fphar-09-00887-g001){#F1}

SNI
---

The SNI surgery was performed as previously described ([@B11]). Rats were anesthetized with 10% chloral hydrate (3 ml/kg) and then the skin of left thigh was incised. The sciatic nerve and its three terminal branches after bluntly dissecting biceps femoris muscle were totally exposed. The common peroneal and tibial nerves were ligated with a 4-0 silk and cut off the distal to the ligation. The muscle and skin were sutured with a 4-0 silk. Rats in the sham group were exposed to the sciatic nerve and its three terminal branches but without ligated and cut off the common peroneal and tibial nerves.

MWT
---

Before MWT, rats were placed in plexiglass chambers with a wire net floor for 30 min avoiding the stress resulting from the test conditions. The Electronic Von Frey (UGO BASILE S.R.L., Italy) filaments were applied to the lateral 1/3 of right paws. The paws quick withdrawal or flinching was considered as a positive response. Every filament stimuli were applied 4 times with a period of 30 s interval ([@B11]).

SPT
---

Rats were exposed to water and 1% sucrose solution for 48 h, followed by 24 h of water and food deprivation and a 24 h exposure to two identical bottles, one is water, and another is 1% sucrose solution. The bottles containing water and sucrose were weighed before and at the end of this period and the sucrose preference was determined ([@B11]).

Western Blot
------------

Samples were homogenized with RIPA buffer (150 mM sodium chloride, Triton X-100, 0.5% sodium deoxycholate, 0.1% sodium dodecyl sulfate, 50 mM Tris, pH 8.0) at 4°C for 30 min, then were centrifuged for 15 min at 4°C. BCA protein assay kit (Boster, Wuhan, China) was used to determine the protein levels in supernatant. The samples were separated by 10% sodium dodecyl sulfate-polyacrylamide gel electrophoresis and were transferred to polyvinylidene fluoride membranes (Millipore, Bedford, MA, United States). Bands were blocked with 5% BSA in TBST (0.1% Tween 20 in Tris-buffered saline) for 1 h at room temperature. Relative primary antibodies were incubated at 4°C overnight: rabbit Keap1 (1:1,000, Affinity, Cincinnati, OH, United States), rabbit Nrf2 (1:1,000; Affinity, Cincinnati, OH, United States), and mouse GAPDH (1:1,000, Qidongzi, Wuhan, China). Then bands were washed with TBST and incubated second antibody for 2 h at room temperature: goat anti-rabbit IgG horseradish peroxidase or goat anti-mouse IgG horseradish peroxidase (1:5,000, Qidongzi, Wuhan, China). Finally, these bands were detected by enhanced chemiluminescence reagents (Qidongzi, Wuhan, China) with the ChemiDoc XRS chemiluminescence imaging system (Bio-Rad, Hercules, CA, United States).

Statistical Analyses
--------------------

The data show as the mean ± standard error of the mean (SEM). Analysis was performed using PASW Statistics 20 (formerly SPSS Statistics; SPSS). Comparisons between groups were performed using the one-way analysis of variance (ANOVA) or two-way ANOVA, followed by *post hoc* Tukey test. In Hierarchical cluster analysis, the data were firstly standardized by *z*-scores. Then, hierarchical cluster analysis of SPT results was performed using Ward's method and applying squared Euclidean distance as the distance measure, and mice were classified as anhedonia-susceptible rats or anhedonia-resilient rats ([@B11]). The *P*-values of less than 0.05 were considered statistically significant.

Results
=======

Comparison of MWT and SPT Among the Sham, Anhedonia-Susceptible and Anhedonia-Resilient Rats
--------------------------------------------------------------------------------------------

A total of 25 SNI rats were divided into anhedonia-susceptible and anhedonia-resilient groups by hierarchical clustering analysis of SPT results (**Figure [1B](#F1){ref-type="fig"}**). MWT was significantly decreased in both anhedonia-susceptible and anhedonia-resilient rats as compared with that of sham on day 7, 14, and 21 after SNI surgery (**Figure [1C](#F1){ref-type="fig"}**). However, there was no any change in the MWT between anhedonia-susceptible and anhedonia-resilient rats (**Figure [1C](#F1){ref-type="fig"}**). Furthermore, the sucrose preference in the anhedonia-susceptible rats was significantly lower than those in the sham or anhedonia-resilient rats on day 5, 12, and 19 after SNI (**Figure [1D](#F1){ref-type="fig"}**).

Altered Expression of Keap1 and Nrf2 in Selected Tissues in Sham, Anhedonia-Susceptible, and Anhedonia-Resilient Rats
---------------------------------------------------------------------------------------------------------------------

There were significant alterations in the levels of Keap1 protein in the mPFC, hippocampus, L2-5 spinal cord, muscle, and liver in the SNI-treated rats. *Post hoc* test showed a significant decrease of Keap1 protein in the mPFC, hippocampus and muscle in anhedonia-susceptible rats than that of sham and anhedonia-resilient rats (**Figures [2A,C,E](#F2){ref-type="fig"}**). Interestingly, there was a significant decrease of Keap1 protein in the L2-5 spinal cord and liver in anhedonia-susceptible rats than that of sham rats although there were no changes in the spinal cord and liver between anhedonia-susceptible and anhedonia-resilient rats (**Figures [2D,F](#F2){ref-type="fig"}**). In contrast, there were no changes of Keap1 in the NAc among the three groups (**Figure [2B](#F2){ref-type="fig"}**).

![Expression of Keap1 and Nrf2 proteins in selected tissues among the sham, anhedonia-susceptible, and anhedonia-resilient groups. **(A)** Keap1 \[*F*~(2,15)~ = 9.477~,~ *P* = 0.02\] and Nrf2 \[*F*~(2,15)~ = 11.497~,~ *P* = 0.013\] levels in the mPFC. **(B)** Keap1 \[*F*~(2,15)~ = 1.811, *P* = 0.243\] and Nrf2 \[*F*~(2,15)~ = 0.289, *P* = 0.759\] levels in the NAc. **(C)** Keap1 \[*F*~(2,15)~ = 10.833~,~ *P* = 0.01\] and Nrf2 \[*F*~(2,15)~ = 9.248~,~ *P* = 0.015\] levels in the hippocampus. **(D)** Keap1 \[*F*~(2,15)~ = 62.237~,~ *P* = 0.011\] and Nrf2 \[*F*~(2,15)~ = 31.095~,~ *P* \< 0.001\] levels in the L2-5 spinal cord. **(E)** Keap1 \[*F*~(2,15)~ = 6.35~,~ *P* = 0.033\] and Nrf2 \[*F*~(2,15)~ = 144.8~,~ *P \<* 0.001\] levels in the muscle. **(F)** Keap1 \[*F*~(2,15)~ = 25.886~,~ *P* = 0.001\] and Nrf2 \[*F*~(2,15)~ = 22.201~,~ *P* = 0.002\] levels in the liver. Data are shown as mean ± SEM (*n* = 6). ^∗^*P* \< 0.05, ^∗∗^*P* \< 0.01, or ^∗∗∗^*P* \< 0.01. Keap1, kelch-like ECH-associated protein 1; mPFC, medial prefrontal cortex; NAc, nucleus accumbens; Nrf2, nuclear factor (erythroid 2-derived)-like 2; N.S., not significant.](fphar-09-00887-g002){#F2}

Anhedonia-susceptible rats showed a significant decrease of Nrf2 protein in the mPFC, hippocampus, spinal cord, and muscle compared to sham or anhedonia-resilient rats (**Figures [2A,C](#F2){ref-type="fig"}**). In contrast, the expression of Nrf2 protein in the NAc from anhedonia-susceptible rats was no difference among the three groups (**Figure [2B](#F2){ref-type="fig"}**). In the liver, both anhedonia-susceptible and anhedonia-resilient rats significantly decreased levels of Nrf2 compared to sham rats, but there was no significant change between the two groups (**Figure [2F](#F2){ref-type="fig"}**).

Effects of Subsequent SFN Treatment on the Results of MWT and SPT After SNI Surgery
-----------------------------------------------------------------------------------

Seventeen anhedonia-susceptible rats from 35 SNI rats were selected by hierarchical clustering analysis of SPT results (**Figures [3A,B](#F3){ref-type="fig"}**). The reduction of scores of MWT in anhedonia-susceptible rats after SNI surgery was attenuated significantly after subsequent single administration of SFN (30 mg/kg) (**Figure [3C](#F3){ref-type="fig"}**). In contrast, the reduced sucrose preference in anhedonia-susceptible rats after SNI surgery was not improved after subsequent single administration of SFN (**Figure [3D](#F3){ref-type="fig"}**).

![Effects of SFN treatment after SNI surgery on the results of MWT and SPT. **(A)** The schedule of the experiment. SNI surgery was performed on day 0 after acclimation. SFN (30 mg/kg, i.p.) was administered on day 11. SPT was measured on day 5 and 12 after SNI, respectively. MWT was performed on day 7 and 14 after SNI, respectively. **(B)** Dendrogram of hierarchical clustering analysis. A total of 35 SNI rats were divided into anhedonia-susceptible and anhedonia-resilient groups by SPT results. Thirteen-seven of 35 SNI rats were anhedonia-susceptible phenotype. **(C)** MWT \[Time: *F*~(2,42)~ = 160.9~,~ *P* \< 0.001; SFN: *F*~(1,42)~ = 1.635~,~ *P* = 0.208; Interaction: *F*~(2,42)~ = 6.284~,~ *P* = 0.0041\]. Data are shown as mean ± SEM (*n* = 8). ^∗^*P* \< 0.05, SFN group vs. vehicle group. **(D)** SPT \[Time: *F*~(1,28)~ = 3.361~,~ *P* = 0.0774; SFN: *F*~(1,28)~ = 0.04322~,~ *P* = 0.8368; Interaction: *F*~(1,28)~ = 0.9291~,~ *P* = 0.3434\]. Data are shown as mean ± SEM (*n* = 8). MWT, mechanical withdrawal test; N.S., not significant; SFN, sulforaphane; SNI, spared nerve injury; SPT, sucrose preference test.](fphar-09-00887-g003){#F3}

Effects of Subsequent SFN Treatment on the Levels of Keap1-Nrf2 Signaling in Selected Tissues After SNI Surgery
---------------------------------------------------------------------------------------------------------------

A single administration of SFN (30 mg/kg) into anhedonia-susceptible rats after SNI surgery did not alter the levels of Keap1 and Nrf2 in the mPFC, NAc, hippocampus, muscle, and liver (**Figures [4A--C,E,F](#F4){ref-type="fig"}**). In contrast, SFN significantly increased the reduced levels of Keap1 and Nrf2 proteins in the spinal cord of anhedonia-susceptible rats (**Figure [4D](#F4){ref-type="fig"}**). Collectively, it is likely that activation of Keap1-Nrf2 system in the spinal cord by SFN may play a role in the SFN-induced beneficial effects for reduced MWT scores in anhedonia-susceptible rats after SNI.

![Effects of SFN treatment after SNI surgery on the expression of Keap1 and Nrf2 proteins in selected tissues. **(A)** Keap1 (*t* = 0.5248~,~ *P* = 0.6112) and Nrf2 (*t* = 0.9042~,~ *P* = 0.3872) levels in the mPFC. **(B)** Keap1 (*t* = 0.4853~,~ *P* = 0.6379) and Nrf2 (*t* = 0.01363~,~ *P* = 0.9894) levels in the NAc. **(C)** Keap1 (*t* = 0.1111~,~ *P* = 0.9137) and Nrf2 (*t* = 0.3427~,~ *P* = 0.7389) levels in the hippocampus. **(D)** Keap1 (*t* = 5.45~,~ *P* \< 0.001) and Nrf2 (*t* = 3.861~,~ *P* = 0.0032) levels in the L2-5 spinal cord. **(E)** Keap1 (*t* = 0.6394~,~ *P* = 0.5369) and Nrf2 (*t* = 0.4178~,~ *P* = 0.6850) levels in the muscle. **(F)** Keap1 (*t* = 0.463~,~ *P* = 0.6533) and Nrf2 (*t* = 0.3559~,~ *P* = 0.7293) levels in the liver. Data are shown as mean ± SEM (*n* = 6). ^∗∗^*P* \< 0.01 or ^∗∗∗^*P* \< 0.001. Keap1, kelch-like ECH-associated protein 1; mPFC, medial prefrontal cortex; NAc, nucleus accumbens; Nrf2, nuclear factor (erythroid 2-derived)-like 2; N.S., not significant; SFN, sulforaphane.](fphar-09-00887-g004){#F4}

Effects of Pretreatment With SFN on the Results of MWT and SPT After SNI Surgery
--------------------------------------------------------------------------------

Spared nerve injury surgery was performed 30 min after a single administration of SFN (30 mg/kg) or vehicle (**Figure [4A](#F4){ref-type="fig"}**). The ratio of anhedonia-susceptible rats to total SNI rats in vehicle-treated group and SFN-treated group were 50 and 31%, respectively (**Figures [5B](#F5){ref-type="fig"}--[D](#F5){ref-type="fig"}**). Thus, pretreatment with SFN significantly increased the number of anhedonia-resilient rats after SNI surgery (**Figure [5D](#F5){ref-type="fig"}**).

![Effects of SFN treatment before SNI surgery on the results of MWT and SPT. **(A)** The schedule of this study. SNI was performed on day 0 after acclimation. SFN at a single dose of 30 mg/kg was administered 30 min before SNI surgery. MWT was measured on day 5 and 12 after SNI, respectively. SPT was performed on day 7 and 14 after SNI, respectively. **(B)** Dendrogram of hierarchical clustering analysis. A total of 16 SNI rats were divided into anhedonia-susceptible and anhedonia-resilient groups by SPT results. Eight of 16 SNI rats were anhedonia susceptible phenotype. **(C)** Dendrogram of hierarchical clustering analysis. A total of 16 SNI rats were divided into anhedonia-susceptible and anhedonia-resilient groups by SPT results. Five of 16 SNI rats were anhedonia-susceptible phenotype. **(D)** Ratio of anhedonia-susceptible rats to total SNI rats. The ratio of anhedonia-susceptible rats in vehicle and SFN groups were 50 and 31%, respectively. **(E)** MWT \[Time: *F*~(1,16)~ = 8.851~,~ *P* = 0.0089; SFN: *F*~(3,16)~ = 30.58~,~ *P* \< 0.001; Interaction: *F*~(3,16)~ = 0.9991~,~ *P* = 0.4186\]. Data are shown as mean ± SEM (*n* = 5). ^∗^*P* \< 0.05, ^∗∗^*P* \< 0.01 or ^∗∗^*P* \< 0.001. **(D)** SPT \[Time: *F*~(1,16)~ = 32.05~,~ *P* \< 0.001; SFN: *F*~(3,16)~ = 361.7~,~ *P* \< 0.001; Interaction: *F*~(3,16)~ = 7.569~,~ *P* = 0.0023\]. Data are shown as mean ± SEM (*n* = 5). MWT, mechanical withdrawal test; N.S., not significant; SFN, sulforaphane; SNI, spared nerve injury; SPT, sucrose preference test.](fphar-09-00887-g005){#F5}

On day 7, SFN (30 mg/kg) significantly increased the scores of MWT in both anhedonia-susceptible and anhedonia-resilient rats (**Figure [5E](#F5){ref-type="fig"}**). On day 14, SFN-treated rats showed a significant increase in the MWT scores in both anhedonia-susceptible and anhedonia-resilient rats as compared with that of vehicle-treated rats. Furthermore, the MWT scores of SFN-treated anhedonia-resilient rats were significantly higher than those of SFN-treated anhedonia-susceptible rats (**Figure [5E](#F5){ref-type="fig"}**).

There was a significant change in the results of SPT between anhedonia-susceptible rats and anhedonia-resilient rats in both vehicle- and SFN-treated groups on day 5 and 12 (**Figure [5F](#F5){ref-type="fig"}**). On day 5, SFN significantly increased the sucrose preference of anhedonia-resilient rats, but not anhedonia-susceptible rats. On day 12, SFN significantly increased the sucrose preference of susceptible rats, but not resilient rats (**Figure [5F](#F5){ref-type="fig"}**).

Prophylactic Effects of SFN on the Altered Levels of Keap1-Nrf2 Signaling in Selected Tissues After SNI Surgery
---------------------------------------------------------------------------------------------------------------

Pretreatment with SFN (30 mg/kg) significantly increased the Keap1 and Nrf2 levels in the mPFC, hippocampus, spinal cord, muscle, and liver of anhedonia-resilient rats compared to vehicle-treated anhedonia-resilient rats or SFN-treated anhedonia-susceptible rats (**Figures [6A,C--F](#F6){ref-type="fig"}**). However, SFN did not induce any change in the levels of Keap1 and Nrf2 protein in the NAc from anhedonia-resilient rats and anhedonia-susceptible rats (**Figure [6B](#F6){ref-type="fig"}**).

![Effects of SFN treatment before SNI surgery on Keap1-Nrf2 signaling in selected tissues. **(A)** Keap1 \[SFN: *F*~(1,16)~ = 25.1~,~ *P* = 0.001; Phenotype: *F*~(1,16)~ = 26.36~,~ *P* \< 0.001; Interaction: *F*~(1,16)~ = 1.184~,~ *P* = 0.2926\] and Nrf2 \[SFN: *F*~(1,16)~ = 12.9~,~ *P* = 0.0024; Phenotype: *F*~(1,16)~ = 40.27~,~ *P* \< 0.001; Interaction: *F*~(1,16)~ = 0.2745~,~ *P* = 0.6075\] levels in the mPFC. **(B)** Keap1 \[SFN: *F*~(1,16)~ = 3.965~,~ *P* = 0.0638; Phenotype: *F*~(1,16)~ = 9.697~,~ *P* = 0.0067; Interaction: F~(1,16)~ = 0.2142~,~ *P* = 0.6497\] and Nrf2 \[SFN: *F*~(1,16)~ = 0.088~,~ *P* = 0.7706; Phenotype: *F*~(1,16)~ = 0.6729~,~ *P* = 0.4241; Interaction: *F*~(1,16)~ = 0.8057~,~ *P* = 0.3827\] levels in the NAc. **(C)** Keap1 \[SFN: *F*~(1,16)~ = 11.79~,~ *P* = 0.0034; Phenotype: *F*~(1,16)~ = 41.42~,~ *P* \< 0.001; Interaction: *F*~(1,16)~ = 2.94~,~ *P* = 0.1057\] and Nrf2 \[SFN: *F*~(1,16)~ = 12.01~,~ *P* = 0.0032; Phenotype: *F*~(1,16)~ = 23.12~,~ *P* \< 0.001; Interaction: *F*~(1,16)~ = 4.539~,~ *P* = 0.049\] levels in the hippocampus. **(D)** Keap1 \[SFN: *F*~(1,16)~ = 20.69~,~ *P* \< 0.001; Phenotype: *F*~(1,16)~ = 49.2~,~ *P* \< 0.001; Interaction: *F*~(1,16)~ = 0.3084~,~ *P* = 0.5863\] and Nrf2 \[SFN: *F*~(1,16)~ = 13.11~,~ *P* = 0.0023; Phenotype: *F*~(1,16)~ = 34.32~,~ *P* \< 0.001; Interaction: *F*~(1,16)~ = 1.179~,~ *P* = 0.2936\] levels in the L2-5 spinal cord. **(E)** Keap1 \[SFN: *F*~(1,16)~ = 4.55~,~ *P* = 0.0488; Phenotype: *F*~(1,16)~ = 291.3~,~ *P* \< 0.001; Interaction: *F*~(1,16)~ = 149.2~,~ *P* \< 0.001\] and Nrf2 \[SFN: *F*~(1,16)~ = 27.85~,~ *P* \< 0.001; Phenotype: *F*~(1,16)~ = 6.673~,~ *P* = 0.02; Interaction: *F*~(1,16)~ = 3.469~,~ *P* = 0.081\] levels in the muscle. **(F)** Keap1 \[SFN: *F*~(1,16)~ = 14.27~,~ *P* = 0.0017; Phenotype: *F*~(1,16)~ = 9.022~,~ *P* = 0.0084; Interaction: *F*~(1,16)~ = 1.393, *P* = 0.2551\] and Nrf2 \[SFN: *F*~(1,16)~ = 6.814, *P* = 0.0189; Phenotype: *F*~(1,16)~ = 13.18~,~ *P* = 0.0023; Interaction: *F*~(1,16)~ = 5.598~,~ *P* = 0.0309\] levels in the liver. Data are shown as mean ± SEM (*n* = 5). ^∗^*P* \< 0.05, ^∗∗^*P* \< 0.01, or ^∗∗∗^*P* \< 0.001. Keap1, kelch-like ECH-associated protein 1; mPFC, medial prefrontal cortex; NAc, nucleus accumbens; Nrf2, nuclear factor (erythroid 2-derived)-like 2; N.S., not significant; SFN, sulforaphane.](fphar-09-00887-g006){#F6}

Discussion
==========

The present study demonstrated that although SNI rats suffered almost identical nociceptive damage, some rats exhibited anhedonia-like phenotypes. Tissue levels of Keap1 and Nrf2 in mPFC, hippocampus, and muscle of rats with anhedonia-like phenotypes were lower than those in rats without anhedonia-like phenotypes and sham-operated rats. Furthermore, tissue levels of Keap1 and Nrf2 in the spinal cord and liver of rats with anhedonia-like phenotypes were lower than those of sham rats. Decreased MWT scores, but not decreased sucrose preference, in susceptible rats following SNI surgery were attenuated with subsequent single administration of SFN (30 mg/kg). Furthermore, SFN significantly improved the decreased Keap1 and Nrf2 expression levels in the spinal cord of susceptible rats following SNI. Moreover, SFN treatment (30 mg/kg) prior to SNI surgery significantly ameliorated the reduced MWT scores, anhedonia-like behavior, and decreased Keap1-Nrf2 signaling in mPFC, hippocampus, and spinal cord of rats with anhedonia-like phenotypes. To the best of our knowledge, this is the first study demonstrating the role of the Keap1-Nrf2 system in individual differences of anhedonia after neuropathic pain. In addition, this is the first study to establish the role of Keap1-Nrf2 signaling in the prophylactic and therapeutic effects of SFN in the comorbidity of neuropathic pain and depression in rodents.

In preclinical studies, depression-related behaviors of hyperalgesic rats were highly diverse. Using resident-intruder social interaction and sleep--wake analyses, it is reported that chronic constriction injury induced a subgroup (approximately 30%) of rats with altered dominant behavior ([@B20]) and sleep--wake cycle ([@B3]). In the present study, hierarchical cluster analysis was used to divide SNI rats into two clusters: one group (approximately 68%; anhedonia-like phenotype) with reduced sucrose preference in the SPT and the other (approximately 32%; without anhedonia-like phenotype) with sucrose preference similar to that in sham-operated rats, consistent with our previous report ([@B11]). In the current study, we also found that rats, regardless of the presence or absence of anhedonia-like phenotype, exhibited similar MWT scores, suggesting that alterations in mood-related behaviors were independent of the degree of nociceptive damage, which was consistent with previous studies ([@B20]; [@B3]; [@B2]; [@B12]; [@B36]; [@B11]).

We identified decreased Keap1-Nrf2 signaling in mPFC and hippocampus of rats with anhedonia-like phenotypes on day 23 following SNI. Low levels of Keap1-Nrf2 in mPFC and hippocampus are reportedly associated with the development of depression-like phenotypes, including anhedonia, in rodents ([@B38]; [@B41]). Furthermore, *Nrf2* knockout mice demonstrated depression-like phenotype, including anhedonia ([@B39]). A recent study using postmortem brain samples exhibited reduced Keap1 and Nrf2 expression levels in the parietal cortex of depressed patients ([@B40]), suggesting that decreased Keap1-Nrf2 signaling plays a role in depression. Interestingly, SFN did not improve the decreased sucrose preference in rats with anhedonia-like phenotypes, although it significantly attenuated decreased MWT scores through the improvement of the Keap1-Nrf2 system in the spinal cord of rats with anhedonia-like phenotype. Thus, it appears that Keap1-Nrf2 signaling in the spinal cord plays a role in pain following SNI. Overall, it is likely that decreased Keap1-Nrf2 signaling in mPFC and hippocampus is associated with anhedonia-like phenotype in rats with neuropathic pain, and that Nrf2 activators, including SFN, have therapeutic potential in patients with neuropathic pain-associated anhedonia.

In this study, we found that SNI rats with anhedonia-like phenotype had lower tissue Keap1 and Nrf2 levels in the spinal cord than those in sham-operated rats. Given the role of Keap1-Nrf2 signaling in pain ([@B14]; [@B23]), reduced Keap1-Nrf2 signaling in the spinal cord may play a role in neuropathic pain, although not in anhedonia-like phenotypes.

Skeletal muscle, which consumes two-third of the body's energy supply, comprises approximately 40% of the body mass in a healthy individual with normal body weight ([@B24]). Following skeletal muscle injury, Nrf2 activity is required for muscle regeneration and effective healing by regulating satellite cell proliferation ([@B27]) and preventing inflammation-induced muscle wasting and fibrosis ([@B1]). In the present study, we also found decreased Keap1 and Nrf2 expression levels in the muscle of anhedonia-susceptible rats. Furthermore, these levels were significantly lower than those in the muscle of anhedonia-resilient rats. Thus, decreased Keap1-Nrf2 signaling in the muscle may contribute to anhedonia susceptibility to SNI surgery, although further detailed studies are warranted.

In addition, we found decreased Keap1 and Nrf2 expression levels in the liver of rats with or without anhedonia-like phenotype following SNI surgery. Hence, it is unlikely that Keap1 and Nrf2 signaling alterations in the liver contribute to anhedonia susceptibility to SNI surgery. Given the role of the Keap1-Nrf2 system in the host cell defense against oxidative stress ([@B15]; [@B30]; [@B21]; [@B31]; [@B34]; [@B6]; [@B37]), decreased Keap1-Nrf2 signaling in the liver may play a role in oxidative stress in the liver of SNI rats. Nonetheless, further detailed studies regarding the underlying role of Keap1-Nrf2 signaling in the brain and peripheral tissues (spinal cord, muscle, and liver) are needed.

In the present study, we used a single injection of SFN (30 mg/kg) in a rat SNI model. Our previous studies demonstrated that dietary intake of glucoraphanin (a precursor of SFN) can prevent the onset of behavioral abnormalities and biochemical changes in the brain following phencyclidine administration ([@B29]), inflammation ([@B41]), chronic social defeat stress ([@B38]), and maternal immune activation ([@B17]). Collectively, dietary intake of glucoraphanin during the experimental period may show prophylactic effects in reducing MWT and SPT scores following SNI surgery. Therefore, further study on the long-term administration of SFN (or glucoraphanin) is of great interest. These results suggested that SFN or its precursor glucoraphanin could potentially be used for the treatment of anhedonia in patients with neuropathic pain, because they are naturally occurring compounds found in cruciferous vegetables. Finally, further study regarding the dietary intake of glucoraphanin-rich vegetables (or SFN supplements) in depressed patients with neuropathic pain is necessary to study their prophylactic effects.

Conclusion
==========

The current study suggests that decreased Keap1-Nrf2 signaling in mPFC, hippocampus, and muscle is associated with individual differences of the anhedonia-like phenotype in rats with neuropathic pain, whereas in the spinal cords of SNI rats, it is associated with neuropathic pain. Therefore, it is likely that Nrf2 activators, including SFN, are a potential therapeutic target for comorbid pain and anhedonia in patients with neuropathic pain.
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